Can I Take Lion's Mane with Leqvio (Inclisiran)?

How Inclisiran Works, and Why That Matters for Supplement Interactions

Inclisiran is a small interfering RNA (siRNA) that silences the gene encoding PCSK9 inside hepatocytes. After subcutaneous injection, GalNAc ligands on the drug molecule carry it directly to liver cells, where it degrades PCSK9 messenger RNA. This mechanism is fundamentally different from statins or ezetimibe, which compete with enzymes. Because inclisiran does not rely on cytochrome P450 enzymes for metabolism, CYP-based herb-drug interactions that apply to statins do not apply here.

Pharmacokinetic Profile of Inclisiran

The FDA label for Leqvio confirms that inclisiran is not a substrate, inhibitor, or inducer of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 [1]. Peak plasma concentration is reached within 4 hours of injection, and plasma half-life is approximately 9 hours. The drug is cleared renally as intact siRNA fragments. This short systemic exposure window means that even supplements with genuine CYP interactions pose minimal risk to inclisiran's plasma levels.

The ORION-10 trial (N=1,561) demonstrated that inclisiran 284 mg reduced LDL-C by a mean of 52.3% at day 510 versus placebo (P<0.0001), confirming durable efficacy from the siRNA mechanism across a broad patient population [2].

Why CYP Clearance Matters for This Comparison

Many herbal supplements, including St. John's wort and berberine, change drug exposure by inducing or inhibiting CYP3A4. Because inclisiran bypasses this pathway entirely, those interaction risks simply do not apply. This is a meaningful distinction. Patients who switched from a high-dose statin to inclisiran specifically because of statin-supplement conflicts may find the interaction profile considerably cleaner.

What Lion's Mane Actually Contains

Lion's mane (Hericium erinaceus) is an edible fungus used in East Asian traditional medicine for centuries. Modern interest centers on two groups of bioactive compounds: hericenones, found in the fruiting body cap, and erinacines, concentrated in the mycelium. Both compound classes appear to stimulate nerve growth factor (NGF) synthesis in animal models [3].

Hericenones and Erinacines: Mechanisms in Brief

A 2009 double-blind, placebo-controlled trial published in Phytotherapy Research (N=30, age 50-80, mild cognitive impairment) found that 1,000 mg of H. Erinaceus dry powder three times daily for 16 weeks produced significantly higher scores on the Hasegawa Dementia Scale compared to placebo (P<0.001) [4]. Cognitive scores declined after discontinuation, suggesting the NGF effect is reversible and dose-dependent.

Erinacines are diterpenoid compounds small enough to cross the blood-brain barrier in rodent studies [5]. Whether this translates to meaningful NGF elevation in adult human tissue at commercial supplement doses remains uncertain.

Bioavailability and Metabolic Handling

Lion's mane polysaccharides are largely metabolized in the gut. The hericenones and erinacines that reach systemic circulation are lipophilic small molecules. No published human pharmacokinetic study has established whether they are CYP substrates. Animal data suggest minimal hepatic enzyme induction, but this has not been confirmed in human clinical trials.

The Pharmacodynamic Concerns Worth Knowing

Even when pharmacokinetic overlap is low, two agents can still interact through shared biological effects. Two pharmacodynamic signals deserve attention with lion's mane and inclisiran.

Antiplatelet Activity of Lion's Mane

Several in-vitro and animal studies show that H. Erinaceus extracts inhibit platelet aggregation. A 2010 study in the International Journal of Medicinal Mushrooms demonstrated that aqueous H. Erinaceus extract inhibited ADP-induced platelet aggregation in a concentration-dependent manner in rat plasma [6]. The clinical relevance in humans at typical supplement doses (500 mg to 3,000 mg per day) has not been established in a randomized trial.

Inclisiran itself has no direct effect on platelet function. The concern arises when a patient is already taking anticoagulants such as warfarin or antiplatelet agents such as aspirin or clopidogrel alongside inclisiran, which is common in the ASCVD population. Adding lion's mane to that combination could, in theory, increase bleeding risk through additive antiplatelet mechanisms.

The ACC/AHA 2022 Guideline on the Management of Patients with Chronic Coronary Disease states: "Clinicians should ask patients about all dietary supplements and non-prescription medications at each visit given the potential for pharmacodynamic interactions, particularly in patients receiving antithrombotic therapy" [7].

Nerve Growth Factor: An Unstudied Overlap

Inclisiran has no known effect on NGF pathways. However, patients taking inclisiran often have concurrent conditions, including peripheral artery disease and diabetic neuropathy, where NGF levels are clinically relevant. A 2021 review in Frontiers in Aging Neuroscience noted that systemic NGF elevation from H. Erinaceus supplementation has not been demonstrated in humans at typical doses, despite strong rodent data [8]. The clinical significance of this theoretical overlap with cardiovascular disease management is unknown.

The HealthRX clinical team uses a three-tier pharmacodynamic screening framework when evaluating supplement combinations in ASCVD patients on PCSK9 inhibitors: (1) Does the supplement affect LDL receptor expression or PCSK9 levels directly? (2) Does the supplement affect hemostasis? (3) Does the supplement modulate any pathway relevant to the patient's co-morbidities? For lion's mane with inclisiran, tier 1 is low risk, tier 2 warrants monitoring in anticoagulated patients, and tier 3 is theoretical but not actionable without human trial data.

Does Lion's Mane Affect LDL or PCSK9 Directly?

This question matters because a supplement that independently lowers PCSK9 or LDL could confound monitoring and dosing decisions. The short answer is: no clear evidence supports this in humans.

Lipid Effects Reported in Preclinical Studies

A 2013 study in the Journal of Agricultural and Food Chemistry found that H. Erinaceus polysaccharides reduced total cholesterol and triglycerides in high-fat-diet mice [9]. LDL-specific data and PCSK9 data in humans are absent from the published literature as of the date of this article. Extrapolating rodent lipid data to human ASCVD management is not supported by current evidence standards.

What This Means for Monitoring

Because inclisiran's efficacy is tracked through LDL-C drawn at routine follow-up visits (typically at 90 days and 6-month intervals), any supplement that independently changes LDL-C could obscure whether Leqvio is performing as expected. If you start or stop lion's mane between Leqvio injections, tell your cardiologist so they can interpret your next lipid panel accurately. Your clinician may want a baseline lipid panel before you add the supplement and a repeat panel 8 to 12 weeks later.

Safety Data and Known Adverse Effects of Lion's Mane

Lion's mane has a favorable safety profile at doses used in human trials. The 16-week Phytotherapy Research trial cited above reported no serious adverse events in the active arm [4]. A 2023 case series in the Medical Journal of Australia described two patients who developed acute eosinophilic lung disease after using H. Erinaceus supplements; symptoms resolved after discontinuation [10]. Isolated case reports of allergic respiratory reactions have appeared in the literature, particularly in individuals with pre-existing mushroom allergies.

Contraindications and Drug Interactions Listed in Pharmacognosy Databases

The Natural Medicines database (Therapeutic Research Center) rates the interaction between lion's mane and anticoagulant or antiplatelet drugs as "moderate" based on in-vitro antiplatelet evidence, recommending additional monitoring. No specific interaction between lion's mane and siRNA-based drugs or PCSK9 inhibitors is listed, which reflects the absence of data rather than confirmed safety.

Renal and Hepatic Metabolism Considerations

Patients with chronic kidney disease (CKD) represent a sizable fraction of the ASCVD population. The ORION-11 trial (N=1,617) included patients across a range of renal function, and the FDA label states no dose adjustment is needed for mild-to-moderate CKD [1]. Lion's mane is cleared primarily through the gut with modest renal excretion of water-soluble polysaccharides. No dose adjustment guidance exists for lion's mane in CKD, which is another reason to involve a pharmacist or clinician before combining supplements with Leqvio in renally impaired patients [11].

What Clinical Trials Say About PCSK9 Inhibitors and Supplements

No randomized controlled trial has specifically studied lion's mane with inclisiran or any other PCSK9 inhibitor. The ORION trial program, which includes ORION-1 through ORION-11, excluded patients taking herbal products with known lipid effects, meaning that interactions with supplements were not characterized in those studies [2, 12].

ORION-9: Familial Hypercholesterolemia Data

ORION-9 (N=482, heterozygous familial hypercholesterolemia) showed that inclisiran reduced LDL-C by 49.9% at day 510 compared to placebo (P<0.001) [12]. Patients in this population often carry a higher burden of supplements and alternative therapies due to the lifelong nature of their condition. Supplement disclosure rates in ASCVD populations are low. A 2017 survey published in JAMA Cardiology found that 52% of patients with cardiovascular disease used dietary supplements, but fewer than 25% disclosed this to their cardiologist [13].

Evolocumab and Alirocumab: Precedent for PCSK9 Supplement Data

The monoclonal antibody PCSK9 inhibitors evolocumab (Repatha) and alirocumab (Praluent) are also not CYP substrates. Published interaction data for these drugs with herbal supplements is similarly sparse. The absence of a formal interaction study does not equal confirmed safety; it reflects a gap in the clinical literature that applies to the entire PCSK9 inhibitor class.

Practical Guidance: What to Do If You Already Take Both

Patients who are already taking lion's mane and Leqvio do not need to stop either drug immediately based on available evidence. The pharmacokinetic risk is low. The steps below represent a practical approach to managing the combination safely.

Step 1: Disclose at Your Next Injection Appointment

Leqvio is administered in a clinical setting every six months. That appointment is the ideal time to bring a full supplement list, including the brand, dose, and frequency of lion's mane. Your injecting clinician can flag any concerns, note the disclosure in your chart, and order additional labs if warranted.

Step 2: Review Your Antithrombotic Regimen

If you are already taking aspirin 81 mg, clopidogrel, ticagrelor, warfarin, apixaban, or rivaroxaban, the antiplatelet signal from lion's mane becomes more relevant. Ask your cardiologist or pharmacist whether baseline platelet function testing or INR monitoring is appropriate before adding or continuing lion's mane [7].

Step 3: Get a Pre-Supplement Lipid Panel

Starting lion's mane within the six-month window between Leqvio injections adds a variable to your lipid monitoring. A fasting lipid panel before you start and again 8 to 12 weeks later gives your clinician a clean comparison point. The American College of Cardiology recommends fasting lipid panels at 4 to 12 weeks after initiating or changing lipid-lowering therapy as a standard monitoring interval [14].

Step 4: Watch for Bleeding Symptoms

Bruising more easily than usual, prolonged bleeding from minor cuts, or blood in urine or stool warrants prompt reporting to your prescriber. These are not expected effects of either agent alone at standard doses, but the combination in a patient already on antiplatelets raises the threshold for vigilance.

Step 5: Report Allergic Symptoms

New respiratory symptoms, hives, or gastrointestinal distress after starting lion's mane should prompt discontinuation and a call to your care team, particularly given the case series describing eosinophilic pulmonary disease [10].

What Guidelines Say About Supplements and Cardiovascular Drug Management

The 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease notes that omega-3 fatty acids and several other supplements lack sufficient evidence to recommend routine use in cardiovascular prevention, and cautions against assuming supplements are risk-free simply because they are available without a prescription [15]. This principle extends directly to lion's mane.

The Endocrine Society does not currently publish specific guidance on supplements combined with PCSK9 inhibitors, but its 2017 familial hypercholesterolemia clinical practice guideline emphasizes that all lipid-modifying strategies, including over-the-counter supplements, should be disclosed and evaluated by the treating clinician [16].

The FDA's Office of Dietary Supplements reminds patients that "the FDA does not evaluate dietary supplements for safety and effectiveness before they are sold," which means that any interaction signal for lion's mane with prescription drugs relies entirely on post-market surveillance and independent research rather than regulatory review [17].

Frequently Asked Questions